XOMA price target raised to $10 from $8 at Canaccord Canaccord raised its price target for XOMA shares to $10 from $8 despite the erosive osteoarthritis of the hand trial failure. The firm said the setting was never part of its model and that its raised target reflects the pyoderma gangrenosum data. Canaccord reiterates a Buy rating on XOMA.
News For XOMA From The Last 14 Days
Check below for free stories on XOMA the last two weeks.